ATTO Technology, Inc.
Michelle Seifert has over 20 years of experience in international sales and business development. Michelle worked at ATTO Technology from 1995 until present, where they were responsible for developing and maintaining the international sales presence. Michelle worked with various customers and engaged in strategic planning and team leadership. Prior to that, they worked at GP:50 from 1990 to 1996, supporting the marketing director with sales and marketing activities, including press releases, brand recognition, and trade shows. Michelle also oversaw the ordering process and provided support to product lines.
Michelle Seifert began their education in 1991 at Canisius, where they studied Civil Engineering. Michelle attended Canisius for one year, completing their studies in 1992. Following that, they enrolled at NCCC, pursuing a degree in Engineering. The end year for their education at NCCC is not provided.
This person is not in any offices
ATTO Technology, Inc.
Since 1985, Atto Bioscience (formerly Atto Instruments) has provided innovative solutions to pharmaceutical, academic, and research groups in cellular biology. Combining the proven expertise of its top scientists with its unique, flexible, and easily-integrated technology, Atto redefines cellular research and drug discovery with customized andinnovative approaches that enhance any research process.Atto’s key competitive advantage is the ability to integrate biology, imaging instrumentation, engineering, and manufacturing and to deliver to the life science, pharmaceutical and toxicology community a comprehensive offering of assays, instrumentation and services. Their in-house design and development of technology affords us a better understanding of application areas allowing us to adapt to the demands of their customers, and to quickly engineer and develop state-of-the-art imaging solutions to meet those demands.In the summer of 2001, Atto reorganized to expand into the drug discovery market place. As part of the reorganization Atto expanded their management and business teams and has doubled the size of the company over the last year.Atto also strengthened its scientific teams by bringing in some of the lead scientists in cell and molecular biology also from Life Technologies.These new personnel additions along with new venture money have allowed Atto to aggressively move into the high-throughput cell imaging marketplace. From secondary screening techniques to pre-clinical research, Atto technologies and expertise creates improved strategies for reducing time and increasing downstream success.